Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022
October 31 2022 - 6:50AM
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:
EGRX) today announced that the Company will release its 2022 third
quarter financial results on Monday, November 7, 2022, before the
market opens.
Scott Tarriff, President and Chief Executive Officer, and Brian
Cahill, Chief Financial Officer, will host a conference call to
discuss the results as follows:
Date |
|
Monday,
November 7, 2022 |
Time |
|
8:30 a.m. ET |
Toll free (U.S.) |
|
800-343-4849 |
International |
|
785-424-1699 |
|
|
|
Webcast (live and replay) |
|
www.eagleus.com, under the “Investor Relations” section |
A replay of the conference call will be available for two weeks
after the call's completion by dialing 800-934-4548 (U.S.) or
402-220-1175 (International) and entering conference call ID
EGRXQ322. The webcast will be archived for 30 days at the
aforementioned URL.
About Eagle Pharmaceuticals, Inc. Eagle is a
fully integrated pharmaceutical company with research and
development, clinical, manufacturing and commercial expertise.
Eagle is committed to developing innovative medicines that result
in meaningful improvements in patients’ lives. Eagle’s
commercialized products include vasopressin, PEMFEXY®, RYANODEX®,
BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS®
through its wholly-owned subsidiary Acacia Pharma Inc. Eagle’s
oncology and CNS/metabolic critical care pipeline includes product
candidates with the potential to address underserved therapeutic
areas across multiple disease states. Additional information is
available on Eagle’s website at www.eagleus.com.
Contact:Investor Relations for Eagle
Pharmaceuticals, Inc:Lisa M. WilsonT:
212-452-2793E: lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024